NasdaqGM:XENEBiotechs
What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders
Xenon Pharmaceuticals recently presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology 2026 meeting, showing azetukalner meaningfully reduced focal onset seizure frequency versus placebo in highly treatment-resistant adult patients.
Multi-year open-label extension results and real-world survey data highlight azetukalner’s long-term seizure control and the potential practical benefit of a once-daily, no-titration epilepsy therapy for both patients and physicians.
With...